[Somatostatin in active psoriatic arthritis].
In a pilot study on 8 patients with established psoriatic arthritis of all degrees of severity the therapeutic effect of a two-day continuous infusion of Somatostatin was examined. During the first three weeks following the beginning of infusion five patients showed a significant improvement of the clinical picture. In the other three patients no remarkable influence on their psoriatic arthropathic disease was observed. These results encourage further examinations on the efficacy of Somatostatin on psoriatic arthritis.
D001168:Arthritis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007263:Infusions, Parenteral; D010865:Pilot Projects; D011565:Psoriasis / Q000188:drug therapy*; D013004:Somatostatin / Q000009:adverse effects / Q000627:therapeutic use*
D013004:Somatostatin
Somatostatin bei aktiver Psoriasis-Arthritis.